CREST syndrome
Overview
CREST syndrome, also known as limited scleroderma and more commonly referred to today as limited cutaneous systemic sclerosis (lcSSc), is a subtype of systemic sclerosis, a chronic autoimmune connective tissue disease. It is characterized by immune system dysfunction, damage to small blood vessels, and progressive fibrosis (hardening and thickening) of the skin and connective tissues.
Common Symptoms
The term CREST refers to five characteristic features of the disease:
- Calcinosis cutis: This means calcium deposits form in your skin. They look like firm, white or yellow bumps and often appear on your joints, fingertips and face.
- Raynaud’s phenomenon: This means you have occasional spasms in your small blood vessels in places like your fingers and toes. They’re painful and make your digits turn blue.
- Esophageal dysmotility: This means the muscles in your esophagus don’t move as effectively as they should. It can cause chronic acid reflux and difficulty swallowing.
- Sclerodactyly: This means scarring of the skin on your fingers. The skin can become so tight and rigid that it causes contractures in your fingers, making them hard to bend.
- Telangiectasias: These are dilated (widened) capillaries under your skin that appear as red or purple marks. They might look like dots, spider angiomas or spider veins.
Coexisting Diseases and Conditions
Sjögren’s syndrome, SLE, autoimmune thyroiditis, hypothyroidism, rheumatoid arthritis, cardiovascular disease, type 1 diabetes, fibromyalgia, isolated pulmonary artery hypertension, myocardium, and sclerosis of the GI tract.
Risk Factors and Prevalence
Studies have found a greater prevalence of CREST syndrome in females, African Americans, and Choctaw Native Americans. Exposure to silica is an environmental factor associated with the disease.
Recent Research
- Symptom experience of limited cutaneous systemic sclerosis from the Patients’ perspective: A qualitative study✰,✰✰,★,★★ (2021)
- Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohort (2022)
- [18F]Sodium Fluoride PET has the potential to identify active formation of calcinosis cutis in limited cutaneous systemic sclerosis (2022)
- Hemorrhagic Cardiac Tamponade as a Complication of Limited Cutaneous Systemic Sclerosis (2023)
Sources
- Sources
Arnett, F. C., Howard, R. F., Tan, F., Moulds, J. M., Bias, W. B., Durban, E., Cameron, H. D., Paxton, G., Hodge, T. J., Weathers, P. E., & Reveille, J. D. (1996). Increased prevalence of systemic sclerosis in a Native American tribe in Oklahoma. Association with an Amerindian HLA haplotype. Arthritis and rheumatism, 39(8), 1362–1370. https://doi.org/10.1002/art.1780390814.
Lescoat, A., Cavalin, C., Ballerie, A., Lecureur, V., Sesé, L., Cazalets, C., Lederlin, M., Coiffier, G., Belhomme, N., Paris, C., Garlantézec, R., Jouneau, S., & Jégo, P. (2020). Silica Exposure and Scleroderma: More Bridges and Collaboration between Disciplines Are Needed. American journal of respiratory and critical care medicine, 201(7), 880–882. https://doi.org/10.1164/rccm.201911-2218LE.
Scleroderma Foundation. (n.d.). What is scleroderma? What is scleroderma? – Scleroderma Foundation. https://www.scleroderma.org/site/SPageServer/?pagename=patients_whatis#.YLf8rH1KiqC.